Overcoming Hypoxia-Induced Functional Suppression of NK Cells

May 28, 2020

Kristen Solocinski 1, Michelle R Padget 1, Kellsye P Fabian 1, Benjamin Wolfson 1, Fabiola Cecchi 2, Todd Hembrough 2, Stephen C Benz 3, Shahrooz Rabizadeh 2 4, Patrick Soon-Shiong 2 4, Jeffrey Schlom 1, James W Hodge 5
Affiliations expand
PMID: 32345623 PMCID: PMC7213912 DOI: 10.1136/jitc-2019-000246

Contact us at


How Can ImmunityBio Help You?

Solutions for Patients

Many therapies for treating cancer and infectious disease severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Immunotherapies and cell therapies are key to future cancer treatments. Our investigational IL-15 superagonist, N-803, and NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.

Solutions for Research Scientists

Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.